Literature DB >> 23015228

Patients with well-established ankylosing spondylitis show limited deterioration in a ten-year prospective cohort study.

E L Healey1, K L Haywood, K P Jordan, A M Garratt, J C Packham.   

Abstract

This study aims to describe the deterioration of well-established ankylosing spondylitis (AS) over a 10-year period. Patients with well-established AS under secondary care review were assessed at baseline and re-assessed after a 10-year period. Data on patient characteristics, spinal mobility and self-reported health status (AS Quality of Life, Bath AS Disease Activity Index, EuroQoL, Revised Leeds Disability Questionnaire and Short Form-12) were compared between the two time points. One hundred fifty-nine patients took part in the initial assessment. After 10 years, 69/117 patients still under secondary care follow-up attended a second assessment. At the second assessment, this cohort was predominately male (92.8 %), mean age of 48.7 years (SD 9.7) and mean disease and symptom duration of 14.9 (SD 9.0) and 21.9 years (SD 13.3), respectively. Amongst the physical and patient-reported measures, only tragus to wall (p < 0.001), cervical rotation (p = 0.001) and disability (p = 0.02) had significantly deteriorated over time. The percentage of patients who had withdrawn from the workforce before normal retirement age increased from 37 to 53 % over the 10-year period. Many of the measures used in the assessment of AS do not generally deteriorate over time in those with well-established disease. This suggests that deterioration may plateau in established disease. However, AS has a long-term social impact with levels of employment in this cohort 30 % lower than the general population. Interventions directed at preventing deterioration may be more effective earlier in their disease course, before this plateau is reached.

Entities:  

Mesh:

Year:  2012        PMID: 23015228     DOI: 10.1007/s10067-012-2092-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  26 in total

Review 1.  Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys.

Authors:  S M M Verstappen; J W J Bijlsma; H Verkleij; E Buskens; A A M Blaauw; E J ter Borg; J W G Jacobs
Journal:  Arthritis Rheum       Date:  2004-06-15

2.  Impact of ankylosing spondylitis on work in patients across the UK.

Authors:  E L Healey; K L Haywood; K P Jordan; A Garratt; J C Packham
Journal:  Scand J Rheumatol       Date:  2010-08-20       Impact factor: 3.641

Review 3.  Quality of life in patients with ankylosing spondylitis.

Authors:  M M Ward
Journal:  Rheum Dis Clin North Am       Date:  1998-11       Impact factor: 2.670

4.  Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis.

Authors:  L C Doward; A Spoorenberg; S A Cook; D Whalley; P S Helliwell; L J Kay; S P McKenna; A Tennant; D van der Heijde; M A Chamberlain
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

5.  Functional assessment in ankylosing spondylitis: evaluation of a new self-administered questionnaire and correlation with anthropometric variables.

Authors:  C A Abbott; P S Helliwell; M A Chamberlain
Journal:  Br J Rheumatol       Date:  1994-11

6.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

7.  The natural disease course of ankylosing spondylitis.

Authors:  S Carette; D Graham; H Little; J Rubenstein; P Rosen
Journal:  Arthritis Rheum       Date:  1983-02

8.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

9.  Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness.

Authors:  K L Haywood; A M Garratt; K Jordan; K Dziedzic; P T Dawes
Journal:  Rheumatology (Oxford)       Date:  2004-04-07       Impact factor: 7.580

10.  Reducing work disability in Ankylosing Spondylitis: development of a work instability scale for AS.

Authors:  Gill Gilworth; Paul Emery; Nick Barkham; M Glyn Smyth; Philip Helliwell; Alan Tennant
Journal:  BMC Musculoskelet Disord       Date:  2009-06-16       Impact factor: 2.362

View more
  5 in total

1.  Evaluation of the temperament and character properties of patients with ankylosing spondylitis.

Authors:  F Gokmen; K Altinbas; A Akbal; M Celik; Y Savas; E Gökmen; H Reşorlu; A Karaca
Journal:  Z Rheumatol       Date:  2014-11       Impact factor: 1.372

2.  Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab.

Authors:  Mariagrazia Lorenzin; Augusta Ortolan; Paola Frallonardo; Francesca Oliviero; Leonardo Punzi; Roberta Ramonda
Journal:  BMC Musculoskelet Disord       Date:  2015-07-24       Impact factor: 2.362

3.  Exercise habits and C-reactive protein may predict development of spinal immobility in patients with ankylosing spondylitis.

Authors:  Björn Sundström; Lotta Ljung; Solveig Wållberg-Jonsson
Journal:  Clin Rheumatol       Date:  2018-07-18       Impact factor: 2.980

4.  No deterioration in health-related quality of life in patients with axial spondyloarthritis followed for 5 years in ordinary outpatient clinics in the biological treatment era.

Authors:  Gudrun Rohde; Kari Hansen Berg; Are Hugo Pripp; Anne Prøven; Glenn Haugeberg
Journal:  Qual Life Res       Date:  2019-09-26       Impact factor: 4.147

5.  Screening of underlying genetic biomarkers for ankylosing spondylitis.

Authors:  Xutao Fan; Bao Qi; Longfei Ma; Fengyu Ma
Journal:  Mol Med Rep       Date:  2019-04-24       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.